Amarna Therapeutics Partners with NorthX Biologics to Advance Nimvec™ AM510 Gene Therapy Development
December 03, 2024 16:10 ET
|
Amarna Therapeutics
Amarna Therapeutics Partners with NorthX Biologics to Advance Nimvec™ AM510 Gene Therapy Development Leiden, The Netherlands, 3 December 2024 - Amarna Therapeutics, (“Amarna” or “the Company”), a...
Multiplex Assays Market Size & Share to Surpass USD 5.9 billion by 2031 | Analysis by Transparency Market Research, Inc.
November 04, 2024 02:42 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Nov. 04, 2024 (GLOBE NEWSWIRE) -- The global multiplex assays market (멀티플렉스 분석 시장) is estimated to be valued at US$ 5.9...
PolTREG launches Phase 2 cell therapy trial in children with presymptomatic diabetes
October 24, 2024 01:00 ET
|
PolTREG S.A.
Treating diabetes patients earlier with PTG-007 could provide functional cureRecruitment will go ahead after European Medicines Agency approvalCompany has 12 years’ worth of safety...
Tumor Necrosis Factor Inhibitor Drugs Market to hit USD 50 billion by 2032, says Global Market Insights Inc.
October 02, 2024 05:42 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Tumor Necrosis Factor Inhibitor Drugs Market size valued at USD 41.3 billion in 2023 and is projected to grow at a CAGR of 2.2% from...
PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases
September 26, 2024 01:00 ET
|
PolTREG S.A.
Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate developmentNew CAR-Treg cell therapy...
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
September 16, 2024 01:00 ET
|
PolTREG S.A.
China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal administration of PolTREG’s PTG-007 Treg cell therapy to...
PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence
September 09, 2024 01:00 ET
|
PolTREG S.A.
PTG-007 cell therapy resulted in clinical remission in some patients for up to 12 yearsA proportion of patients remained insulin-independent for up to 24 monthsPTG-007 ready to enter pivotal studyData...
SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases
July 09, 2024 02:00 ET
|
SciRhom GmbH
The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary...
GRI Bio Regains Compliance with Nasdaq
July 08, 2024 09:05 ET
|
GRI Bio, Inc.
LA JOLLA, CA, July 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
PolTREG’s type-1 diabetes Treg cell therapy PTG-007 demonstrates long-term safety and efficacy for up to 12 years
June 24, 2024 01:30 ET
|
PolTREG S.A.
PTG-007 administration resulted in improved remission and insulin secretion Patients monitored for up to 12 yearsPlanned pivotal Phase 2/3 study is final step for PolTREG to...